Condition: Refractory Leukemia · Sponsor: Shanghai Jiao Tong University School of Medicine
The investigators developed a protocol combining chemotherapy of cladribine, cytarabine and etoposide (CLAGE) as debulking treatment sequential with reduced intensity conditioning regimen Flu-Bu to treat patients with refractory acute myeloid leukemia (AML). In this study, the aim is to further evaluate the efficacy and feasibility of the protocol with modifications: 1) reduced dose of CLAGE; 2) Reduced intensity conditioning (RIC) regimen as fludarabine, busulfan and melphalan (MBF) or total marrow irradiation (TMI); 3) Venetoclax was added to the chemotherapy and conditioning regimen.
This description comes directly from the study's public registry record.
Jiong HU · 86-21-64370045 · hj10709@rjh.com.cn
Jieling Jiang · +8613311986505 · jiangjieling66@hotmail.com
Always discuss trial participation with your own doctor first.
| Blood & Marrow Transplantation Center, RuiJin Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Department of Hematology, Shanghai No 6 Hospital | Shanghai, China | Recruiting |
| Shanghai ZhaXin Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05870995